Gold Nanocages as Photothermal Transducers for Cancer Treatment

Gold nanocages represent a new class of nanomaterials with compact size and tunable optical properties in the near‐infrared region. They passively accumulate in the tumor after intravenous injection. By exposing tumors to a near‐infrared diode laser, the photothermal effect of the Au nanocages selec...

Full description

Saved in:
Bibliographic Details
Published inSmall (Weinheim an der Bergstrasse, Germany) Vol. 6; no. 7; pp. 811 - 817
Main Authors Chen, Jingyi, Glaus, Charles, Laforest, Richard, Zhang, Qiang, Yang, Miaoxian, Gidding, Michael, Welch, Michael J., Xia, Younan
Format Journal Article
LanguageEnglish
Published Weinheim WILEY-VCH Verlag 09.04.2010
WILEY‐VCH Verlag
Subjects
Animals
cancer treatment
Cell Line, Tumor
Fluorodeoxyglucose F18
Gold - administration & dosage
Gold - pharmacokinetics
Gold - therapeutic use
gold nanocages
Humans
Injections, Intravenous
Light
Metal Nanoparticles - administration & dosage
Metal Nanoparticles - therapeutic use
Mice
Neoplasms - diagnostic imaging
Neoplasms - pathology
Neoplasms - therapy
photothermal transducers
plasmonic materials
Polyethylene Glycols - chemistry
Positron-Emission Tomography
Spectrophotometry, Ultraviolet
Spectroscopy, Near-Infrared
Temperature
Tissue Distribution
Tomography, X-Ray Computed
Transducers
Xenograft Model Antitumor Assays
Online AccessGet full text

Cover

More Information
Summary:Gold nanocages represent a new class of nanomaterials with compact size and tunable optical properties in the near‐infrared region. They passively accumulate in the tumor after intravenous injection. By exposing tumors to a near‐infrared diode laser, the photothermal effect of the Au nanocages selectively destroys tumor tissue with minimum damage to the surrounding healthy tissue.
Bibliography:This work was supported in part by a Director's Pioneer Award from the NIH (DP1 OD000798) and startup funds from Washington University in St. Louis (to Y.X.), as well as a Research Development Award from the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine (to J.C.). Siteman is supported by Grant P30 CA91842 from the NIH. The Inveon small animal PET/CT system, a component of the Siteman Small Animal Cancer Imaging Core, was acquired using an NIH-NCRR shared instrumentation grant (S10 RR025097, to R. L.). Part of the work was performed at the Nano Research Facility (NRF), a member of the National Nanotechnology Infrastructure Network (NNIN), which is supported by the NSF under award no. ECS-0335765. J.C. and C.G. contributed equally to the work.
istex:C5380290B55C3C5F0466D7DE56C7AB5337CD1BB1
ark:/67375/WNG-DMMMHR3G-7
ArticleID:SMLL200902216
This work was supported in part by a Director's Pioneer Award from the NIH (DP1 OD000798) and startup funds from Washington University in St. Louis (to Y.X.), as well as a Research Development Award from the Alvin J. Siteman Cancer Center at Barnes‐Jewish Hospital and Washington University School of Medicine (to J.C.). Siteman is supported by Grant P30 CA91842 from the NIH. The Inveon small animal PET/CT system, a component of the Siteman Small Animal Cancer Imaging Core, was acquired using an NIH‐NCRR shared instrumentation grant (S10 RR025097, to R. L.). Part of the work was performed at the Nano Research Facility (NRF), a member of the National Nanotechnology Infrastructure Network (NNIN), which is supported by the NSF under award no. ECS‐0335765. J.C. and C.G. contributed equally to the work.
These two authors contributed equally to this work.
ISSN:1613-6810
1613-6829
DOI:10.1002/smll.200902216